Pfizer and biontech receive positive chmp opinion for omicron kp.2-adapted covid-19 vaccine in the european union

Upon authorization by the european commission, the omicron kp.2-adapted covid-19 vaccine will be available for individuals 6 months of age and older data demonstrate that the omicron kp.2-adapted covid-19 vaccine generates a substantially improved response against multiple circulating omicron jn.1 sublineages as did the omicron jn.1-adapted covid-19 vaccine authorized by the european commission in july 2024 doses will be ready to ship to applicable european union member states as soon as possible upon european commission authorization new york and mainz, germany, september 20, 2024 — pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the committee for medicinal products for human use (“chmp”) of the european medicines agency (“ema”) has recommended marketing authorization for the companies' omicron kp.2-adapted monovalent covid-19 vaccine (comirnaty® kp.2) for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. the european commission (“ec”) will review the chmp's recommendation and is expected to make a final decision soon.
BNTX Ratings Summary
BNTX Quant Ranking